Neuland Laboratories Ltd banner

Neuland Laboratories Ltd
NSE:NEULANDLAB

Watchlist Manager
Neuland Laboratories Ltd Logo
Neuland Laboratories Ltd
NSE:NEULANDLAB
Watchlist
Price: 13 276 INR 5.05% Market Closed
Market Cap: ₹170.3B

Gross Margin

49.3%
Current
Declining
by 1.6%
vs 3-y average of 50.9%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
49.3%
=
Gross Profit
₹7.8B
/
Revenue
₹15.8B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
49.3%
=
Gross Profit
₹7.8B
/
Revenue
₹15.8B

Peer Comparison

Country Company Market Cap Gross
Margin
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
170.3B INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
959.3B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
585.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
293B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
235.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
243B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
305.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
151.4B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
122.5B USD
Loading...

Market Distribution

In line with most companies in India
Percentile
65th
Based on 4 996 companies
65th percentile
49.3%
Low
-3 052.3% — 26.9%
Typical Range
26.9% — 53.3%
High
53.3% — 8 269.1%
Distribution Statistics
India
Min -3 052.3%
30th Percentile 26.9%
Median 39%
70th Percentile 53.3%
Max 8 269.1%

Neuland Laboratories Ltd
Glance View

Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.

NEULANDLAB Intrinsic Value
6 169.43 INR
Overvaluation 54%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
49.3%
=
Gross Profit
₹7.8B
/
Revenue
₹15.8B
What is Neuland Laboratories Ltd's current Gross Margin?

The current Gross Margin for Neuland Laboratories Ltd is 49.3%, which is below its 3-year median of 50.9%.

How has Gross Margin changed over time?

Over the last 3 years, Neuland Laboratories Ltd’s Gross Margin has increased from 46.6% to 49.3%. During this period, it reached a low of 46.6% on Dec 31, 2022 and a high of 55% on Mar 31, 2024.

Back to Top